PepGen to Participate in the Leerink Global Healthcare Conference

PepGen Inc. (Nasdaq: PEPG), a forward-thinking clinical-stage biotechnology company, is set to participate in the Leerink Global Healthcare Conference. The event is scheduled for Tuesday, March 10, 2026, at 3:00 p.m. ET in Miami, Florida, where CEO Dr. James McArthur will engage in a fireside chat. Investors and stakeholders can access the event through a live webcast on PepGen's website, specifically in the "Events & Presentations" section. A recorded version of the discussion will also be available for 90 days post-event.

PepGen specializes in advancing next-generation oligonucleotide therapies aimed at transforming treatments for severe neuromuscular and neurological diseases. The company's innovative approach is encapsulated in its Enhanced Delivery Oligonucleotide (EDO) platform, which integrates over a decade of research and development. This platform employs cutting-edge cell-penetrating peptides to enhance the uptake and effectiveness of oligonucleotide therapeutics.

Through these EDO peptides, PepGen has developed a robust pipeline of therapeutic candidates designed to target the underlying causes of serious diseases. This strategic focus positions PepGen as a significant player in the biotech sector, as it continues to push the boundaries of treatment options available for debilitating conditions.

For further exploration of PepGen's initiatives and to stay updated on their progress, interested parties can visit their official website at www.pepgen.com, along with their LinkedIn and X accounts for more interactive engagement. Inquiries regarding investor relations can be directed to Laurence Watts at New Street Investor Relations, while media inquiries can be addressed to Julia Deutsch at Lyra Strategic Advisory. PepGen’s involvement in the Leerink Global Healthcare Conference underscores its commitment to innovation and partnership within the biotechnology landscape.

As PepGen Inc. (Nasdaq: PEPG) prepares to participate in the upcoming Leerink Global Healthcare Conference, this event presents a significant opportunity for investors to gauge the company's direction and future growth potential. Under the leadership of Dr. James McArthur, PepGen's focus on Next-Generation Oligonucleotide (NGO) therapies positions it as a potential leader in treating severe neuromuscular and neurological diseases, an area with substantial unmet medical need.

The Enhanced Delivery Oligonucleotide (EDO) platform, which enhances the uptake and efficacy of therapeutic candidates, could be a game changer in the biotech landscape. This is particularly noteworthy given the recent trends towards personalized medicine and innovative drug delivery systems that improve patient outcomes while managing costs—an increasingly critical factor for healthcare providers and payers alike.

Investors should pay close attention to the themes discussed during the fireside chat, particularly any updates about clinical trial results, partnerships, or collaborations that could bolster PepGen’s position in the market. A strong presentation with credible data could serve to enhance investor confidence and potentially attract new investment, particularly from those focused on cutting-edge biopharmaceutical innovations.

However, it is crucial for investors to consider the inherent risks associated with clinical-stage biotechnology firms, including but not limited to regulatory hurdles, the outcomes of clinical trials, and market competition. These factors can lead to volatility in stock prices.

In conclusion, while the upcoming conference could serve as a catalyst for PepGen’s stock, investors should remain diligent, conducting thorough research and monitoring the company's progress. Given the promising technologies PepGen is pursuing, a strategic approach—balancing both optimism and skepticism—will be essential for informed investment decisions in the biotech sector.